With 80–90% of all astrocytomas and oligodendrogliomas harboring mutations in the isocitrate dehydrogenase (IDH)1 gene, the mutant form of this enzyme is an attractive target in glioma therapy. Here, IDH1 is linked to central nervous system cancer.